A Retrospective Analysis Comparing APCEDEN
            <sup>®</sup>
            Dendritic Cell Immunotherapy with Best Supportive Care in Refractory Cancer

Kumar, Chaitanya; Kohli, Sandeep; Chiliveru, Srikanth; Bapsy, P. P.; Jain, Minish; Attili, Venkata Sathya Suresh; Mohan, Jagan; Vaid, Ashok; Sharan, Bandana

doi:10.2217/imt-2017-0064

Cited by 17 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sipuleucel-T was shown to prolong overall survival by stimulating an immune response against the antigen PAP/PA2024. [131] Kumar et al showed a median survival benefit of 189 days (356 days for treated group vs 147 days for the untreated group) for autologous dendritic cell-based vaccine for management of refractory solid malignancies, including prostate, ovarian, non-small cell lung and colorectal cancers [132].…”

Section: Dc-based Therapiesmentioning

confidence: 99%

Cellular immunotherapies for cancer

Hayes

2020

Ir J Med Sci

View full text Add to dashboard Cite

Cancer is a major burden on the healthcare system, and new therapies are needed. Recently, the development of immunotherapies, which aim to boost or use the immune system, or its constituents, as a tool to fight malignant cells, has provided a major new tool in the arsenal of clinicians and has revolutionized the treatment of many cancers. Cellular immunotherapies are based on the administration of living cells to patients and have developed hugely, especially since 2010 when Sipuleucel-T (Provenge), a DC vaccine, was the first cellular immunotherapy to be approved by the FDA. The ensuing years have seen two further cellular immunotherapies gain FDA approval: tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). This review will give an overview of the principles of immunotherapies before focusing on the major forms of cellular immunotherapies individually, T cell-based, natural killer (NK) cell-based and dendritic cell (DC)-based, as well as detailing some of the clinical trials relevant to each therapy.

show abstract

Section: Dc-based Therapiesmentioning

confidence: 99%

Cellular immunotherapies for cancer

Hayes

2020

Ir J Med Sci

View full text Add to dashboard Cite

show abstract

“…The Indian government agency (CDSCO-Central Drugs Standard Control Organization) approved in 2017 vaccine based on an autologous monocyte-derived DC loaded with tumor lysate (APCEDEN®) for treatment of prostate, ovarian and colorectal cancers, and non–small cell lung carcinoma (Kumar et al, 2017). In phase II clinical trial this vaccine demonstrated well tolerance by patients with refractory solid malignancies (Bapsy et al, 2014) and a survival benefit over 100 days (Kumar et al, 2017).…”

Section: Dendritic Cells: a Brief History Of Anti-tumor Dc-based Vaccmentioning

confidence: 99%

Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles—A Novel Strategy for Enhancement of the Anti-tumor Immune Response

2019

View full text Add to dashboard Cite

Dendritic cell (DC)-based anti-tumor vaccines have great potential for the treatment of cancer. To date, a large number of clinical trials involving DC-based vaccines have been conducted with a view to treating tumors of different histological origins. However, DC-based vaccines had several drawbacks, including problems with targeted delivery of tumor antigens to DCs and prolong storage of cellular vaccines. Therefore, the development of other immunotherapeutic approaches capable of enhancing the immunogenicity of existing DC-based vaccines or directly triggering anti-tumor immune responses is of great interest. Extracellular vesicles (EVs) are released by almost all types of eukaryotic cells for paracrine signaling. EVs can interact with target cells and change their functional activity by delivering different signaling molecules including mRNA, non-coding RNA, proteins, and lipids. EVs have potential benefits as natural vectors for the delivery of RNA and other therapeutic molecules targeted to DCs, T-lymphocytes, and tumor cells; therefore, EVs are a promising entity for the development of novel cell-free anti-tumor vaccines that may be a favourable alternative to DC-based vaccines. In the present review, we discuss the anti-tumor potential of EVs derived from DCs, tumors, and other cells. Methods of EV isolation are systematized, and key molecules carried by EVs that are necessary for the activation of a DC-mediated anti-tumor immune response are analyzed with a focus on the RNA component of EVs. Characteristics of anti-tumor immune responses induced by EVs in vitro and in vivo are reviewed. Finally, perspectives and challenges with the use of EVs for the development of anti-tumor cell-free vaccines are considered.

show abstract

“…Therefore, ongoing trials using DC-based vaccines are evaluating the use of combined immunotherapies to favor DC activation and promote T cell functions, and overcome tumor immune evasion. The Indian government agency (CDSCO-Central Drugs Standard Control Organization) recently approved in 2017 an autologous monocyte-derived and tumor lysate-pulsed mature DC-based vaccine (APCEDEN®) for treatment of four cancer indications (prostate, ovarian, colo-rectal and non-small cell lung carcinoma) (30). The multicentric phase II clinical trial by Bapsy et al (31) demonstrated that this formulation was safe and well-tolerated in patients with refractory solid tumors.…”

Section: Introductionmentioning

confidence: 99%

“…The multicentric phase II clinical trial by Bapsy et al (31) demonstrated that this formulation was safe and well-tolerated in patients with refractory solid tumors. Moreover, the efficacy profile of APCEDEN® therapy demonstrated a survival benefit of >100 days (30).…”

Section: Introductionmentioning

confidence: 99%

Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results

et al. 2019

View full text Add to dashboard Cite

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based vaccination could integrate the current standard of care for the treatment of a large variety of tumors. Due to their proficiency at antigen presentation, DC are key coordinators of the innate and adaptive immune system, and have critical roles in the induction of antitumor immunity. However, despite proven immunogenicity and favorable safety profiles, DC-based immunotherapies have not succeeded at inducing significant objective clinical responses. Emerging data suggest that the combination of DC-based vaccination with other cancer therapies may fully unleash the potential of DC-based cancer vaccines and improve patient survival. In this review, we discuss the recent efforts to develop innovative personalized DC-based vaccines and their use in combined therapies, with a particular focus on ovarian cancer and the promising results of mutanome-based personalized immunotherapies.

show abstract

A Retrospective Analysis Comparing APCEDEN ^® Dendritic Cell Immunotherapy with Best Supportive Care in Refractory Cancer

Abstract: APCEDEN demonstrated highly convincing survival benefits when compared with the control group.

Cited by 17 publications

References 31 publications

Cellular immunotherapies for cancer

Cellular immunotherapies for cancer

Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles—A Novel Strategy for Enhancement of the Anti-tumor Immune Response

Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results

Contact Info

Product

Resources

About

A Retrospective Analysis Comparing APCEDEN ® Dendritic Cell Immunotherapy with Best Supportive Care in Refractory Cancer

Abstract: APCEDEN demonstrated highly convincing survival benefits when compared with the control group.

Cited by 17 publications

References 31 publications

Cellular immunotherapies for cancer

Cellular immunotherapies for cancer

Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles—A Novel Strategy for Enhancement of the Anti-tumor Immune Response

Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results

Contact Info

Product

Resources

About

A Retrospective Analysis Comparing APCEDEN ^® Dendritic Cell Immunotherapy with Best Supportive Care in Refractory Cancer